LogoLogo
OT PlatformOT GeneticsCommunityBlog
  • Open Targets Platform
  • Getting started
  • Target
    • Tractability
    • Safety
    • Chemical probes & TEPs
    • Baseline expression
    • Molecular interactions
    • Core Gene Essentiality
    • Pharmacogenetics
  • Disease or Phenotype
    • Clinical signs and symptoms
  • 🆕Variant
  • 🆕Study
  • Drug
    • Clinical Precedence
    • Pharmacovigilance
    • Pharmacogenetics
  • 🆕Credible Set
  • Target–disease evidence
  • Target–disease associations
  • 🆕GWAS & functional genomics
    • Data sources
    • Fine-mapping
    • Colocalisation
    • Locus-to-Gene (L2G)
    • Gentropy
  • Bibliography
  • Web interface
    • Associations on the Fly
    • Target Prioritisation
    • Evidence pages
    • Entity profile pages
  • Data and code access
    • Download datasets
    • Google BigQuery
    • GraphQL API
    • 🆕Platform infrastructure
    • 🆕Data pipeline
  • 🆕FAQs
  • Release notes
  • Citation
  • Licence
    • Terms of use
  • Partner Preview Platform
Powered by GitBook
On this page
  • Overview
  • Data sources
  • Publications

Was this helpful?

Export as PDF
  1. Target

Pharmacogenetics

Data supporting pharmacogenetics annotation for a target

PreviousCore Gene EssentialityNextDisease or Phenotype

Last updated 2 months ago

Was this helpful?

Overview

Pharmacogenetics is the study of how genetic variation may change your response to a specific drug. Through the integration of pharmacogenetics data into the Platform, our objective is to apply clinical annotations available in the Pharmacogenetics Knowledgebase (PharmGKB) to aid target prioritisation for drug discovery.

We also enhance these annotations by adding detailed annotations on variant consequence prediction, drug response categories, and specific drug information and whether the gene is a direct target of the drug. This process involves applying advanced phenotype extraction techniques to offer a refined representation of phenotypes, thereby providing a more precise understanding of the genetic determinants influencing treatment outcomes.

Data sources

is an NIH-funded comprehensive resource that provides information about how human genetic variation affects response to medications. PharmGKB collects, curates and disseminates knowledge about clinically actionable gene–drug associations and genotype–phenotype relationships, focusing on the impact of genetic variation on drug response for clinicians and researchers.

We have modelled and harmonised the data from the section of PharmGKB, which provides information about variant–drug pairs based upon collating and summarising variant annotations. Variant annotations are curated manually from a scientific publication. Clinical Annotations then provide an overarching summary and curated for the association between a genetic variant and particular drug responses based on multiple variant annotations. The likely consequence for each genotype of the variant on drug response is represented, in comparison to the other genotypes of that variant.

We have also included annotations for star (*) alleles, a nomenclature used in the pharmacogenetics field for representing key functional variants involved in drug responses.


Publications

When using this data please remember to acknowledge the sources:

Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, Klein TE. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2021 Sep;110(3):563-572. doi: 10.1002/cpt.2350. Epub 2021 Jul 22. PMID: 34216021; PMCID: PMC8457105.

Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96. PMID: 22992668; PMCID: PMC3660037.

PharmGKB
Clinical Annotation
level of evidence
See all relevant PharmGKB publications.